search
Back to results

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
INT131 besylate
Pioglitazone HCl
Placebo
Sponsored by
InteKrin Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes, diabetes, diabetes mellitus, diabetes mellitus, type 2, non-TZD, thiazolidinedione, selective peroxisome proliferator-activated receptor gamma modulator, SPPARM, peroxisome proliferator-activated receptor gamma, PPAR gamma, insulin sensitizer, glucose control, endocrinopathy, hypoglycemic agent, sulfonylurea, metformin, pioglitazone, nutritional and metabolic diseases

Eligibility Criteria

30 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of Type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose
  • Males and Females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age
  • HbA1c must be ≥7.5% and ≤10% at screening
  • Fasting Plasma Glucose must be <240 mg/dL at screening

Exclusion Criteria:

  • History of type 1 diabetes
  • History of diabetic ketoacidosis
  • NYHA Class III or IV cardiac status or hospitalization for congestive heart failure within 6 weeks prior to Visit 1
  • Treatment with any non-peroxisome proliferator-activated receptor (non-PPAR) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening
  • Treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic agent within 6 month prior to screening
  • Body mass index >45 kg/m2
  • Fasting triglycerides >500 mg/dL
  • Uncontrolled hypertension (sitting systolic blood pressure >160 mmHg and/or sitting diastolic blood pressure >100 mmHg
  • Presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)

Sites / Locations

  • Northern California Research
  • National Research Institute
  • VA San Diego Healthcare System
  • Apex Research Institute
  • Internal Medicine of the Rockies
  • Creekside Endocrine Associates, PC
  • Clinical Research Consulting, LLC
  • MedStar Research Institute
  • Clinical Research of South Florida
  • The Center for Diabetes and Endocrine Care
  • Baptist Diabetes Associates, PA
  • International Research Associates, LLC
  • Elite Research Institute
  • Suncoast Clinical Research, Inc.
  • Suncoast Clinical Research, Inc.
  • Meridien Research
  • Meridien Research
  • Clinical Research of Central Florida
  • Executive Health and Research Associates, Inc.
  • Endocrine Research Solutions, Inc.
  • Cedar-Crosse Research Center
  • ICCT Reseach International
  • American Health Network
  • L-Marc Research Center
  • New Orleans Center for Clinical Research
  • Stephen R. Smith, MD
  • Olive Branch Family Medical Center
  • Diabetes and Endocrinology Specialists, Inc.
  • Saint Luke's Lipid and Diabetes Reseach Center
  • Bozeman Deaconess Internal Medicine Associates
  • Comprehensive Clinical Research
  • Kaleida Health Diabetes Center
  • UNC Diabetes Care Center/Highgate Specialty Center
  • Fairbrook Medical Clinic
  • Diabetes & Endrocrinology Consultants
  • The Lindner Clinical Trial Center
  • IVA Research
  • Rapid Medical Research, Inc
  • Opitmed Research, LTD
  • ResEvo LLC
  • Delaware Smith Clinic
  • Prestige Clinical Research
  • Wells Institute for Health Awareness
  • Frederick C Smith Clinic
  • Your Diabetes Endocrine Nutrition Group, LLC
  • Clinical Research Source, Inc
  • Tri-State Medical Group, Inc.
  • Lycoming Internal Medicine, Inc.
  • New England Center for Clinical Research
  • Hartwell Research Group
  • Medical Research South
  • Palmetto Clinical Trial Services, LLC
  • Dallas Diabetes and Endocrine Research Center
  • Research Institute of Dallas
  • Baylor University Endocrine Center
  • Diabetes Center of the Southwest
  • Quality Research, Inc.
  • DGD Research
  • Salem VA Medical Center R&D Office
  • Nucleo Medico Vallarta
  • Comite Mexicano para la Prevencion de la Osteoporosis A.C.
  • Centro Especializado en Diabetes y Obisidad (EDOPEC)
  • Instituto Nacional de Nutricion Salvador Zubiran (INNSZ)
  • Instituto Mexicano de Investigacion Clinica
  • Unidad Metabolica y Cardiovascular SC
  • Hospital Santa Engracia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Active Comparator

Placebo Comparator

Arm Label

INT131 besylate 0.5 mg

INT131 besylate 1 mg

INT131 besylate 2 mg

INT131 besylate 3 mg

pioglitazone HCl 45 mg

placebo

Arm Description

INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.

INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl

INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl

INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl

pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate

placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl

Outcomes

Primary Outcome Measures

Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward
HbA1c is measured as percent. Thus this change from baseline reflects the week 24 HbA1c percent minus the Week 0 HbA1c percent

Secondary Outcome Measures

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.
The change from baseline reflects the Week 24 FPG minus the Week 0 FPG with last observation carried forward.

Full Information

First Posted
February 27, 2008
Last Updated
August 18, 2010
Sponsor
InteKrin Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00631007
Brief Title
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
Official Title
A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2010
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
September 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
InteKrin Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with pioglitazone HCl in patients with type 2 diabetes. Eligible patients will be men and women (of non-childbearing potential or using dual barrier methods of contraception) between 30 and 75 years of age who are minimally responsive to treatment with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes, diabetes, diabetes mellitus, diabetes mellitus, type 2, non-TZD, thiazolidinedione, selective peroxisome proliferator-activated receptor gamma modulator, SPPARM, peroxisome proliferator-activated receptor gamma, PPAR gamma, insulin sensitizer, glucose control, endocrinopathy, hypoglycemic agent, sulfonylurea, metformin, pioglitazone, nutritional and metabolic diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
367 (Actual)

8. Arms, Groups, and Interventions

Arm Title
INT131 besylate 0.5 mg
Arm Type
Experimental
Arm Description
INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
Arm Title
INT131 besylate 1 mg
Arm Type
Experimental
Arm Description
INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
Arm Title
INT131 besylate 2 mg
Arm Type
Experimental
Arm Description
INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
Arm Title
INT131 besylate 3 mg
Arm Type
Experimental
Arm Description
INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
Arm Title
pioglitazone HCl 45 mg
Arm Type
Active Comparator
Arm Description
pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
Intervention Type
Drug
Intervention Name(s)
INT131 besylate
Intervention Description
Once-daily, oral
Intervention Type
Drug
Intervention Name(s)
Pioglitazone HCl
Other Intervention Name(s)
Actos
Intervention Description
Once-daily, oral
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Once-daily, oral
Primary Outcome Measure Information:
Title
Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward
Description
HbA1c is measured as percent. Thus this change from baseline reflects the week 24 HbA1c percent minus the Week 0 HbA1c percent
Time Frame
Weeks 0-24
Secondary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.
Description
The change from baseline reflects the Week 24 FPG minus the Week 0 FPG with last observation carried forward.
Time Frame
Weeks 0-24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of Type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose Males and Females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age HbA1c must be ≥7.5% and ≤10% at screening Fasting Plasma Glucose must be <240 mg/dL at screening Exclusion Criteria: History of type 1 diabetes History of diabetic ketoacidosis NYHA Class III or IV cardiac status or hospitalization for congestive heart failure within 6 weeks prior to Visit 1 Treatment with any non-peroxisome proliferator-activated receptor (non-PPAR) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening Treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic agent within 6 month prior to screening Body mass index >45 kg/m2 Fasting triglycerides >500 mg/dL Uncontrolled hypertension (sitting systolic blood pressure >160 mmHg and/or sitting diastolic blood pressure >100 mmHg Presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Orloff, MD
Organizational Affiliation
Medpace, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Northern California Research
City
Carmichael
State/Province
California
ZIP/Postal Code
95608
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
VA San Diego Healthcare System
City
San Diego
State/Province
California
ZIP/Postal Code
92161
Country
United States
Facility Name
Apex Research Institute
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Facility Name
Internal Medicine of the Rockies
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80910
Country
United States
Facility Name
Creekside Endocrine Associates, PC
City
Denver
State/Province
Colorado
ZIP/Postal Code
80209
Country
United States
Facility Name
Clinical Research Consulting, LLC
City
Milford
State/Province
Connecticut
ZIP/Postal Code
06460
Country
United States
Facility Name
MedStar Research Institute
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20003
Country
United States
Facility Name
Clinical Research of South Florida
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
The Center for Diabetes and Endocrine Care
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Baptist Diabetes Associates, PA
City
Miami
State/Province
Florida
ZIP/Postal Code
33156
Country
United States
Facility Name
International Research Associates, LLC
City
Miami
State/Province
Florida
ZIP/Postal Code
33156
Country
United States
Facility Name
Elite Research Institute
City
Miami
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
Suncoast Clinical Research, Inc.
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
Facility Name
Suncoast Clinical Research, Inc.
City
Palm Harbor
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
Facility Name
Meridien Research
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Meridien Research
City
Tampa
State/Province
Florida
ZIP/Postal Code
34203
Country
United States
Facility Name
Clinical Research of Central Florida
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880
Country
United States
Facility Name
Executive Health and Research Associates, Inc.
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Endocrine Research Solutions, Inc.
City
Roswell
State/Province
Georgia
ZIP/Postal Code
30076
Country
United States
Facility Name
Cedar-Crosse Research Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
ICCT Reseach International
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
American Health Network
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46254
Country
United States
Facility Name
L-Marc Research Center
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40213
Country
United States
Facility Name
New Orleans Center for Clinical Research
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70119
Country
United States
Facility Name
Stephen R. Smith, MD
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21234
Country
United States
Facility Name
Olive Branch Family Medical Center
City
Olive Branch
State/Province
Mississippi
ZIP/Postal Code
38654
Country
United States
Facility Name
Diabetes and Endocrinology Specialists, Inc.
City
Chesterfield
State/Province
Missouri
ZIP/Postal Code
63017
Country
United States
Facility Name
Saint Luke's Lipid and Diabetes Reseach Center
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
Bozeman Deaconess Internal Medicine Associates
City
Bozeman
State/Province
Montana
ZIP/Postal Code
59715
Country
United States
Facility Name
Comprehensive Clinical Research
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Facility Name
Kaleida Health Diabetes Center
City
Buffalo
State/Province
New York
ZIP/Postal Code
14209
Country
United States
Facility Name
UNC Diabetes Care Center/Highgate Specialty Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27713
Country
United States
Facility Name
Fairbrook Medical Clinic
City
Hickory
State/Province
North Carolina
ZIP/Postal Code
28602
Country
United States
Facility Name
Diabetes & Endrocrinology Consultants
City
Morehead City
State/Province
North Carolina
ZIP/Postal Code
28557
Country
United States
Facility Name
The Lindner Clinical Trial Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
IVA Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45245
Country
United States
Facility Name
Rapid Medical Research, Inc
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44122
Country
United States
Facility Name
Opitmed Research, LTD
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43235
Country
United States
Facility Name
ResEvo LLC
City
Cuyahoga Falls
State/Province
Ohio
ZIP/Postal Code
44223
Country
United States
Facility Name
Delaware Smith Clinic
City
Delaware
State/Province
Ohio
ZIP/Postal Code
43015
Country
United States
Facility Name
Prestige Clinical Research
City
Franklin
State/Province
Ohio
ZIP/Postal Code
45005
Country
United States
Facility Name
Wells Institute for Health Awareness
City
Kettering
State/Province
Ohio
ZIP/Postal Code
45429
Country
United States
Facility Name
Frederick C Smith Clinic
City
Marion
State/Province
Ohio
ZIP/Postal Code
43302
Country
United States
Facility Name
Your Diabetes Endocrine Nutrition Group, LLC
City
Mentor
State/Province
Ohio
ZIP/Postal Code
44060
Country
United States
Facility Name
Clinical Research Source, Inc
City
Perrysburg
State/Province
Ohio
ZIP/Postal Code
43551
Country
United States
Facility Name
Tri-State Medical Group, Inc.
City
Beaver
State/Province
Pennsylvania
ZIP/Postal Code
15009
Country
United States
Facility Name
Lycoming Internal Medicine, Inc.
City
Jersey Shore
State/Province
Pennsylvania
ZIP/Postal Code
17740
Country
United States
Facility Name
New England Center for Clinical Research
City
Cranston
State/Province
Rhode Island
ZIP/Postal Code
02920
Country
United States
Facility Name
Hartwell Research Group
City
Anderson
State/Province
South Carolina
ZIP/Postal Code
29621
Country
United States
Facility Name
Medical Research South
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
Palmetto Clinical Trial Services, LLC
City
Simpsonville
State/Province
South Carolina
ZIP/Postal Code
29681
Country
United States
Facility Name
Dallas Diabetes and Endocrine Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Research Institute of Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Baylor University Endocrine Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Diabetes Center of the Southwest
City
Midland
State/Province
Texas
ZIP/Postal Code
79705
Country
United States
Facility Name
Quality Research, Inc.
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States
Facility Name
DGD Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Salem VA Medical Center R&D Office
City
Salem
State/Province
Virginia
ZIP/Postal Code
24153
Country
United States
Facility Name
Nucleo Medico Vallarta
City
Guadalajara
State/Province
Jalisco
Country
Mexico
Facility Name
Comite Mexicano para la Prevencion de la Osteoporosis A.C.
City
Mexico City
State/Province
Mexico DF
ZIP/Postal Code
06100
Country
Mexico
Facility Name
Centro Especializado en Diabetes y Obisidad (EDOPEC)
City
Mexico City
State/Province
Mexico DF
ZIP/Postal Code
11650
Country
Mexico
Facility Name
Instituto Nacional de Nutricion Salvador Zubiran (INNSZ)
City
Mexico City
State/Province
Mexico DF
ZIP/Postal Code
14000
Country
Mexico
Facility Name
Instituto Mexicano de Investigacion Clinica
City
Mexico City
State/Province
Mexico DF
Country
Mexico
Facility Name
Unidad Metabolica y Cardiovascular SC
City
Cuernavaca
State/Province
Morelos
Country
Mexico
Facility Name
Hospital Santa Engracia
City
Monterrey
State/Province
Nuevo Leon
ZIP/Postal Code
66220
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
24722496
Citation
DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL; INT131-007 Study Group. Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014 Jul;37(7):1918-23. doi: 10.2337/dc13-2480. Epub 2014 Apr 10.
Results Reference
derived

Learn more about this trial

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

We'll reach out to this number within 24 hrs